Annual Drug Patent Expirations for LYTGOBI
Lytgobi is a drug marketed by Taiho Oncology and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.
This drug has forty patent family members in twenty-one countries.
The generic ingredient in LYTGOBI is futibatinib. One supplier is listed for this compound. Additional details are available on the futibatinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
